Aurinia Pharmaceuticals Aktie [WKN DE: A1W7D4 / ISIN: CA05156V1022]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Aurinia Pharmaceuticals Inc

01.08.19		Aurinia Pharmaceuticals to Release Second Quarter 2019 Financial Results on August 6, 2019 (Businesswire)
18.07.19		Aurinia Announces Further Strengthening of the Senior Management Team (Businesswire)
27.06.19		Aurinia Shareholders Elect all Eight Directors at 2019 Annual General Meeting (Businesswire)
21.06.19		Aurinia Reminds Shareholders to Vote the YELLOW Proxy Prior to June 24 Deadline (Businesswire)
07.06.19		Aurinia Issues Letter to Shareholders (Businesswire)
04.06.19		Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences (Businesswire)
31.05.19		Aurinia Pharmaceuticals Announces Upcoming Annual General Meeting of Shareholders (Businesswire)
17.05.19		Aurinia Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference (Businesswire)
14.05.19		Aurinia Reports First Quarter 2019 Financial Results and Recent Operational Highlights (Businesswire)
10.05.19		Aurinia Recognizes World Lupus Day and Lupus Awareness Month with Activities Focused on Raising Awareness for Lupus Nephritis (Businesswire)
09.05.19		Aurinia Pharmaceuticals to Release First Quarter 2019 Financial Results on May 14, 2019 (Businesswire)
30.04.19		Aurinia Further Strengthens Its Board of Directors with the Appointment of Dr. Daniel Billen (Businesswire)
24.04.19		Aurinia Pharmaceuticals to Present at the 2019 Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
11.04.19		Aurinia Announces Appointment of Peter Greenleaf as Chief Executive Officer and Board Director and the Elevation of Dr. George M. Milne, Jr. to Chairman of the Board (Businesswire)
19.03.19		Aurinia Reports Fourth Quarter and Full Year 2018 Financial Results and Operational Highlights (Businesswire)
14.03.19		Aurinia Recognizes World Kidney Day and National Kidney Month with New Activities Focused on Raising Awareness for Kidney Disease (Businesswire)
07.03.19		Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results on March 19, 2019 (Businesswire)
27.02.19		Aurinia Closes At-The-Market Facility (Businesswire)
25.02.19		Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis (Businesswire)
20.02.19		Aurinia to Present at the 8th Annual SVB Leerink Global Healthcare Conference New York City (Businesswire)
22.01.19		Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome (Businesswire)
21.01.19		Aurinia to Hold Conference Call and Webcast to Discuss Results of Phase 2 Head-to-Head Study of Voclosporin Ophthalmic Solution versus Restasis® for the Treatment of Dry Eye Syndrome (Businesswire)
11.01.19		9 Pharma Stocks To Watch This Month (RTTNews)
19.12.18		Aurinia to Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco (Businesswire)
30.11.18		Aurinia Establishes at-the-Market Facility (Businesswire)
09.11.18		Aurinia to Participate in November Investor Conferences (Businesswire)
08.11.18		Aurinia Reports Third Quarter Financial Results, Clinical Highlights and Corporate Development (Businesswire)
25.10.18		Aurinia Pharmaceuticals to Release Third Quarter Financial Results and General Business Updates on November 8, 2018 (Businesswire)
25.09.18		Aurinia Completes Enrollment of AURORA, its Phase 3 Clinical Trial for the Treatment of Lupus Nephritis (Businesswire)
19.09.18		Aurinia to Participate in Upcoming Investor Conferences (Businesswire)
28.08.18		Aurinia Announces Participation at the 20th Annual Global Investment Conference in New York City September 4-6, 2018 (Businesswire)
09.08.18		Aurinia Reports Second Quarter Financial Results and Operational Highlights (Businesswire)
11.07.18		Aurinia Initiates Phase 2 Clinical Trial for Voclosporin Ophthalmic Solution for the Treatment of Dry Eye Syndrome (Businesswire)
25.06.18		Aurinia Initiates Clinical Trials Broadening the Development of Voclosporin (Businesswire)
22.06.18		Aurinia Announces Results of Annual General Meeting (Businesswire)
10.05.18		Aurinia Reports First Quarter Financial Results and Operational Highlights (Businesswire)
10.05.18		Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis (Businesswire)
01.05.18		Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018 (Businesswire)
25.04.18		Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018 (Businesswire)
02.04.18		Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018 (Businesswire)
15.03.18		Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights (Businesswire)
28.02.18		Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 (Businesswire)
22.02.18		Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors (Businesswire)
20.02.18		Aurinia Named Company of the Year by LifeSciences BC (Businesswire)
14.02.18		Aurinia Pharmaceuticals Launches New Lupus Nephritis Disease Awareness Program (Businesswire)
08.02.18		Aurinia Enhances Commercial and Business Development Expertise with the Appointment of Joseph P. Hagan to its Board of Directors (Businesswire)
06.02.18		Aurinia to Present at Leerink Partners 7th Annual Global Healthcare Conference (Businesswire)
04.01.18		Aurinia Pharmaceuticals Files New Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus (Businesswire)
11.12.17		Aurinia Pharmaceuticals Added to the NASDAQ Biotech Index (Businesswire)
06.11.17		Aurinia Pharmaceuticals to Release Third Quarter 2017 Financial Results on November 14, 2017 (Businesswire)

Erste Seite Zurück | ... | 2 | 3 | 4 | 5 | Weiter

Newssuche

Meistgelesene Nachrichten

Ripple Kurs Prognose: 10 US-Dollar bereits in wenigen Wochen?

NVIDIA vor Zahlen: Bank of America sieht Mega-Potenzial

Bitcoin & Co.: "Dr. Doom" Roubini prognostiziert Krypto-Blase und warnt Anleger

US-Zölle im Fokus: US-Börsen schließen schwach -- ATX schließt tiefer -- DAX letztlich in Rot -- Märkte in Fernost gehen tiefer aus dem Handel

Mercedes-Benz-Aktie fällt: Gewinneinbruch und niedrigere Dividende

Ceres Power-Aktie mit heftigem Kursrutsch: Bosch kündigt Partnerschaft auf

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	22.02.2025 11:55
Kaufwert:	EUR
	Hinzufügen Speichern